An honest review of Jeuveau, the neuromodulator manufactured by Evolus that's purported to kick in faster and last longer than Botox.

Jeuveau is the newest version of botulinum toxin A, the same active ingredient in the original Botox Cosmetic. Here's what you need to know.

Jeuveau’s formulation is very similar to Botox, but it’s specifically marketed for cosmetic use, which makes it a great ...

Evolus’ injectable neurotoxin, Jeuveau, which was approved in 2019, knows exactly what it is. It’s an aesthetic product, and that’s all it wants to be.

That includes one called Jeuveau. It is 20-30% cheaper than Botox, but experts say it's not necessarily better. Patient Ashlee Menchaca says she likes Botox because there's no downtime and no pain.

This laidback approach to broadening interest and access to neurotoxins appears to be working: Jeuveau revenue grew to $148.9 million in 2022, marking a 49% increase over 2021. Yet there is still room ...

Evolus’ Jeuveau garnered $34.7 million in the fourth quarter and $99.7 million in full-year 2021 sales, rising more than 76% over the $56.5 million it made in 2020.

Jeuveau, which is nicknamed "NewTox," has arrived in this area. WEATHER ALERT Heat Advisory. Full Story. WEATHER ALERT Excessive Heat Warning. Full Story. Live StormTracker 6 and Sky 6. Watch Now.

Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, unveils fresh, new branding for its flagship neurotoxin product, Jeuveau ...

Evolus’ Jeuveau (DWP-450) (prabotulinumtoxinA) will likely prove to be a strong competitor to Allergan’s Botox (botulinum toxin type A) for severe glabellar (frown) lines, with an analyst ...